Profit halved, growth stalled—the capex bet is now the story

The quarter's real story is volume collapse masquerading as margin stability. EBITDA margin held firm at 15.6%, but absolute EBITDA fell 32.4% year-on-year—from ~₹71Cr to ~₹24Cr. That drop is almost entirely a volume/revenue story (−₹10Cr revenue), not a margin break. The profit plunge (PAT −42.7%) compounds further: D&A and interest stayed largely fixed, and tax rate effects wound tighter. Transpek's core chemical business lost share in a soft macro—and with Arclin (the largest customer, likely ₹70–80Cr or 50%+ of revenue) set for contract renewal discussions in Q4 FY27/Q1 FY28, the near-term trajectory hinges on whether that contract holds.

Capex philosophy: Prior ₹200Cr spend (FY21–26) was reactive and maintenance-focused (old plant replacement, thionyl chloride backward integration). Management now signals a willingness to front-load the multi-purpose pilot plant (₹0 Q1 capex yet; ready Feb 2027) and Odisha greenfield (₹250Cr over 5–6 years) ahead of fully validated customer demand. That's a shift toward aggressive/growth posture, though execution risk is high given prior track record.

Revenue growth target downshift (implicit): Prior guidance was 10–12% CAGR (cited on multiple calls). Reality: ₹595Cr (FY19) → ₹621Cr (FY26) = 0.8% actual CAGR. New guidance wraps ambiguity: '15–20% growth this year' (₹151Cr base → ₹174–181Cr) plus 'double revenue in 5–6 years.' Q1 delivered −6.5%, so the aspiration is hedging, not commitment.

Product pipeline timeline slipped: Feb 2025 call promised ₹150–200Cr annual revenue from 3–4 new products by FY27–28. Now (Aug 2026): two products ₹50Cr each by FY28; others 'under development,' no timeline. Battery electrolyte product paused (customer tech changed mid-cycle). One polymer still at pilot stage. Zero new product revenue delivered in Q1 FY27.

Silox investment acknowledged as drag: ₹300Cr holding (45% of market cap) earning ₹5–7Cr dividend (1.7–2.3% yield), illiquid under shareholder agreement. Prior: management silent. Now: Bimal Mehta admitting impasse—Silox won't sell, management can't exit, capital trapped. No concrete exit plan offered.

Price action confirms bearish read. Result announced Fri Aug 07, 2026 pre-close ₹1,280. Day-1 reaction: −4.3%. By day 3: −10.47%. By day 5: −10.94%. The pop didn't hold; the sell-off widened. Market verdict: the numbers confirmed the bear thesis (volume loss, guidance miss, capex risk). Price now ₹1,320 (as of Aug 25), still −9.59% from all-time high ₹1,460. Trading above SMA20 (₹1,236.88), SMA50 (₹1,101.49), SMA200 (₹1,142.91)—technically neutral, but momentum fading. RSI 47.3 (neutral). Volume trend decreasing — retail likely exiting on sentiment deterioration.

Valuation context: Stock down 9.59% from ATH; up 52.78% from 52-week low (₹864). Sitting in the middle of the range, which suggests some bounce-relief but not panic-bottom-fishing yet. Book value overshoot likely given Silox illiquidity (₹300Cr at 1.7–2.3% yield). Drawdown is meaningful but not capitulation.

Institutional flows weak. FII 0.02%, DII 1.05% (Q1 FY27). QoQ: FII flat (no change), DII −0.55pp (trimming), promoter −0.2pp (stable at 57.27%). Minimal FII/DII participation signals either institutional indifference or repositioning to wait for Arclin renewal clarity. Promoter holding steady—no distress signal from insiders.